Our Team

Milestone-focused Leadership Team 
Rothstein_SN.jpg

Sam Rothstein, Ph.D.

Acting CEO and Cofounder

Sam Rothstein brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research projects on their development.  Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer immunotherapy and drug delivery as the CEO of Qrono Inc in 2017.  Since joining industry in 2012, Dr. Rothstein he has brought three complex drug products into IND-enabling studies. Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh. 

Jingjing Sun, Ph.D.

Acting Chief Scientific Officer

Jingjing Sun has more than 10 years of experience developing nanoformulations for cancer therapy, including Duo Oncology's lead product. She is an inventor of 7 issued/pending patents in this field.  She has also published 1 book chapter and 35 peer-reviewed papers in top journals. Dr. Sun is an aspiring Research Instructor in Department of Pharmaceutical Sciences, University of Pittsburgh where she also completed a post doc. She received her Ph.D. in Polymer Chemistry and Physics from University of Chinese Academy of Science.

Song Li, MD, PhD

Chair of Scientific Advisory Board 

Cofounder

Sam Rothstein brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research projects on their development.  Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer immunotherapy and drug delivery as the CEO of Qrono Inc in 2017.  Since joining industry in 2012, Dr. Rothstein he has led $4 million of Small Business Innovation Research projects, bring three complex drug products into IND-enabling studies. Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh. 

Jing Zhou Hou, MD

Chair of Clinical Advisory Board

Cofounder

Sam Rothstein brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research projects on their development.  Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer immunotherapy and drug delivery as the CEO of Qrono Inc in 2017.  Since joining industry in 2012, Dr. Rothstein he has led $4 million of Small Business Innovation Research projects, bring three complex drug products into IND-enabling studies. Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh. 

Steve Thorne, Ph.D.

Chairperson Board of Directors

Cofounder

Steve Thorne currently serves as Chief Scientific Officer of Kalivir and Western Oncolytics. He has many years of experience in the field of cancer immunotherapy, from discovery through clinical testing. As an entrepreneur, he has founded and co-founded several companies, including Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials, Western Oncolytics, Kalivir and Bioeclipse. Steve was previously a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London.

©2020 by Duo Oncology, Pittsburgh PA.

  • Twitter
  • LinkedIn
Sam Rothstein, PhD, is the acting CEO of Duo Oncology and a company cofounder.  He brings more than